Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy

Journal of Rheumatology

Volumn 43, Issue 4, 2016, Pages 745-750

  Durcan, Laura ^a   Winegar, Deborah A ^c   Connelly, Margery A ^c   Otvos, James D ^c   Magder, Laurence S ^b   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c LIPOSCIENCE INC   (United States)

Author keywords

Disease activity; Dyslipidemia; GlycA; Hydroxychloroquine; Nuclear magnetic resonance lipoprotein profile; Systemic lupus erythematosus

Indexed keywords

GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PREDNISONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DRUG USE; ETHNICITY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LIPOPROTEINS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX;

EID: 84982106637     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150437     Document Type: Article

References (34)

1. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
2. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708-19.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
4. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
5. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987;83:503-8.
6. Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533-9.
7. Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: Relationship to cardiovascular risk factors. J Rheumatol 2006;33:539-45.
8. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
9. Gonzàlez M, Ribalta J, Vives G, Iftimie S, Ferré R, Plana N, et al. Nuclear magnetic resonance lipoprotein subclasses and the APOE genotype influence carotid atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 2010;37:2259-67.
10. Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, et al. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J Rheumatol 2007;34:1849-54.
11. Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski K, et al; APPLE investigators. Laboratory markers of cardiovascular risk in pediatric SLE: The APPLE baseline cohort. Lupus 2010;19:1315-25.
12. Urquizu-Padilla M, Balada E, Chacon P, Pérez EH, Vilardell-Tarrés M, Ordi-Ros J. Changes in lipid profile between flare and remission of patients with systemic lupus erythematosus: A prospective study. J Rheumatol 2009;36:1639-45.
13. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175-80.
14. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18:1046-53.
15. Azar M, Lyons TJ, Alaupovic P, Stoner JA, Quiroga C, Kaufman DG, et al; VADT Study Group. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications 2013;27:627-32.
16. Hodge AM, Jenkins AJ, English DR, O'Dea K, Giles GG. NMR-determined lipoprotein subclass profile is associated with dietary composition and body size. Nutr Metab Cardiovasc Dis 2011;21:603-9.
17. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-9.
18. Chung CP, Oeser A, Raggi P, Solus JF, Avalos I, Linton MF, et al. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol 2008;27:1227-33.
19. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. GlycA: A composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 2015;61:714-23.
20. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc 2014;3:e001221.
21. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38:41-54.
22. Enocsson H, Sjöwall C, Kastbom A, Skogh T, Eloranta ML, Rönnblom L, et al. Association of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon-?and a C-reactive protein gene variant. Arthritis Rheumatol 2014;66:1568-73.
23. Mok CC, Birmingham DJ, Ho LY, Hebert LA, Rovin BH. High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res 2013;65:441-7.
24. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
25. Matyus SP, Braun PJ, Wolak-Dinsmore J, Saenger AK, Jeyarajah EJ, Shalaurova I, et al. HDL particle number measured on the Vantera, the first clinical NMR analyzer. Clin Biochem 2015;48:148-55.
26. Matyus SP, Braun PJ, Wolak-Dinsmore J, Jeyarajah EJ, Shalaurova I, Xu Y, et al. NMR measurement of LDL particle number using the Vantera Clinical Analyzer. Clin Biochem 2014;47:203-10.
27. Austin MA, Krauss RM. LDL density and atherosclerosis. JAMA 1995;273:115.
28. García-Gómez C, Nolla JM, Valverde J, Narváez J, Corbella E, Pintó X. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 2008; 38:686-92.
29. Schroeder LL, Tang X, Wasko MC, Bili A. Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. Rheumatol Int 2015;35:1059-67.
30. McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 2011;70:1619-24.
31. Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, et al. New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: The Multi-ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2014;34:196-201.
32. Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: A longitudinal evaluation of the lipid-lowering effect. Lupus 2012;21:1178-82.
33. Migkos MP, Markatseli TE, Iliou C, Voulgari PV, Drosos AA. Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome. J Rheumatol 2014;41:902-8.
34. Kerr G, Aujero M, Richards J, Sayles H, Davis L, Cannon G, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res 2014;66:1619-26.